Have a question?
Please get in touch with our team in case of any queries
THE GLOBAL DRUG-COATED BALLOONS MARKET WAS VALUED AT USD 965.41 MILLION IN 2023 AND IS EXPECTED TO REACH USD 2.31 BILLION BY 2029, GROWING AT A CAGR OF 15.72% DURING THE FORECAST PERIOD.
The Drug-Coated Balloons Market Size, Share & Trend Analysis Report By
- Indication: Peripheral Artery Disease (PAD), Coronary Artery Disease (CAD), and Other Indications
- Drug: Paclitaxel and Sirolimus
- End-Users: Multi-specialty Hospitals and Specialty Hospitals
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
GLOBAL DRUG-COATED BALLOONS MARKET REPORT SCOPE
REPORT ATTRIBUTE | DETAILS |
---|---|
Market Size (2029) | USD 2.31 Billion |
Market Size (2023) | USD 965.41 Million |
CAGR (2023-2029) | 15.72% |
HISTORIC YEAR | 2020-2022 |
BASE YEAR | 2023 |
FORECAST YEAR | 2024-2029 |
MARKET SEGMENTS BY | Indication, Drug, End-Users, and Geography |
GEOGRAPHIC ANALYSIS | North America, Europe, APAC, Latin America, and Middle East & Africa |
KEY PLAYERS | BD, Boston Scientific, B. Braun SE, Medtronic, Koninklijke Philips, and Biotronik |
MARKET INSIGHTS
The global drug-coated balloons market was valued at USD 965.41 million in 2023 and is expected to reach USD 2.31 billion by 2029, growing at a CAGR of 15.72% during the forecast period. The market growth mainly results from promising clinical outcomes over several alternative treatments that drive significant market growth. The increasing potential patient population with peripheral and coronary artery diseases is accelerating the demand for drug-coated balloons. Moreover, the continued advancements and increasing application of drug-coated balloons in large native vessel procedures are expected to deliver lucrative market growth opportunities.
Drug-coated balloon (DCB) is widely used medical devices to prevent and treat restenosis in peripheral and coronary arteries. Drug-coated balloons are also known as drug-eluting balloons. They are semi-compliant angioplasty balloons covered with antiproliferative medicine, which is delivered into the vessel during inflammation of the balloon. DCBs are designed to dilate the stenotic coronary artery while delivering drugs to suppress neointimal hyperplasia.
MARKET TRENDS & DRIVERS
Continuous Advancements in Interventional Cardiology with DCB
The growing burden of cardiovascular diseases is accelerating the continued development of interventional cardiology and has led to the development of drug-coated balloons. Traditional metallic stents represent several limitations in interventional cardiology, where DCBs have clinically proven better for transferring drugs into vessel walls. From in-stent restenosis to several other major CAD scenarios such as complex bifurcations, de novo small and large vessel disease, and diffuse coronary diseases, as well as other critical clinical conditions such as diabetes, acute coronary syndrome, and high bleeding risk patients are becoming the new approaches for drug-coated balloons. It is becoming a new trend in the DCB industry alone or as a part of blended strategies in combination with drug-eluting stents. With the consideration of all these factors, drug-coated balloons have emerged as the most promising option to tackle coronary artery disease (CAD). Currently, the use of DCB in bifurcation lesions is becoming an attractive scenario. The role of DCB in patients with diabetes mellitus is increasing. It is a high-risk health condition impacting overall vascular territories and has shown negative remolding at the coronary sites where DCB shows significantly lower MACE and myocardial infarction (MI). In patients with high bleeding risk, the risk of high bleeding is reduced. These factors indicate that the DCB has significant potential to tackle these new conditions and is expected to deliver significant revenue growth opportunities. There are important technical and scientific advances registered in DCB in interventional cardiology in recent years, and it is expected to increase its application in various cardiology treatments.
Growing Application of Drug-coated Balloons for Large Native Vessels
Drug-coated balloons have been widely accepted in small-vessel diseases in the past few years. However, continued research and efforts have increased the application of DCB in large native vessels. Several factors support the increased investigation and use of DCB in large vessels, resulting in greater safety and better clinical outcomes than other treatments. The use of DCB in large vessel procedures offers several advantages, such as releasing medicine in large vessels without leaving metal or foreign particles behind. It eliminated the risk of stent strut malapposition, specifically in vessels with irregular walls, bifurcations, or aneurismatic dilatation. Furthermore, the increasing use of drug-coated balloons is becoming a popular choice over drug-eluting stents (DES) implantation in large vessel procedures due to high bleeding risk with DES.
Increasing Promising Clinical Outcomes with DCBs
DCB catheter-based interventional procedures are more advanced than other minimally invasive endovascular and open surgical techniques. Interventional procedures with DCBs are associated with fewer complications, higher success rates, and faster recovery rates than other techniques. Owing to such advantages, vascular surgeons and manufacturers recommend using DCBs for treating a wide range of PAD, CAD, and other arterial/vascular diseases. DCBs are designed to deliver antiproliferative medicine/agent to the coronary or peripheral lesion without the use of metallic stent and were considered as an alternative treatment for CAD & PAD, specifically for in-stent restenosis. Among young adults, DCBs are becoming the leading choice due to the lack of a stent in the body for their entire lives. The increasing cases of PAD and CAD among the young population are expected to deliver significant demand for DCBs in the upcoming years. The clinical utilization of DCBs has increased significantly over the past few years due to the introduction of next-generation devices, which have significantly improved the outcome of arterial disease treatment procedures. Restenosis is one of the major challenges/complications in patients who undergo stenting procedures for treating vascular diseases. DCB technology is proven to be more efficient than angioplasty and other open surgical techniques, especially in high-risk and complicated patients whose performing open surgeries, re-stenting, and other minimally invasive procedures is difficult. Treatment with DCBs offers patients a targeted, polymer-free, and homogenous drug delivery designed to overcome angioplasty procedures' limitations/unmet needs. Also, it helps to minimize the number of unnecessary stent implantations. DCBs are considered a novel alternative therapeutic strategy for CAD due to the fast and homogenous transfer of antiproliferative drugs into the vessel wall during single balloon inflation without permanent implants.
INDUSTRY RESTRAINTS
Alternative Interventional Procedures for Drug-coated Balloons
The availability of standard treatment options, the high initial cost of the device, and low awareness regarding DCB technology are hindering the growth prospects of DCBs globally. Over the past decade, major progress has been made in the percutaneous treatment of vascular diseases. Surgical bypass and endovascular procedures such as standard balloon angioplasty, stenting, and endograft are the most widely used treatment procedures for arterial diseases. Conventional balloon angioplasty, which uses standard balloon catheters, is considered the first line of treatment for several arterial diseases. Initially, the advent of balloon angioplasty offered an alternative treatment option for revascularization. Even for ESRD patients undergoing dialysis, physicians opt for plain balloon angioplasty due to their widespread acceptance and the availability of a broad range of commercial balloon catheters. In percutaneous coronary intervention cases, more than 80% of cases proceed with coronary stents over drug-coated balloons. Even for ESRD patients undergoing dialysis, physicians opt for plain balloon angioplasty due to their widespread acceptance and the availability of a broad range of commercial balloon catheters.
SEGMENTATION INSIGHTS
INSIGHTS BY INDICATION
The global drug-coated balloons market by indication type is segmented into peripheral artery disease (PAD), coronary artery disease (CAD), and other indications. The peripheral artery disease segment dominates, with the largest market share. Peripheral artery disease (PAD) is one of the prevalent health conditions associated with atherosclerosis, affecting more than 210 million people in 2023, worldwide. Drug-coated balloons with paclitaxel and sirolimus drug are currently available in the market, which reduces the risk of re-narrowing arteries. Paclitaxel is clinically proven to prevent scar tissue formation in blood vessels that can re-narrow the artery. DCBs have been used in high proportion in recent years in PAD management, as they have proven to improve blood flow to the legs and reduce the requirement for repeat procedures to reopen blocked vessels, thus helping the segment's growth.
INSIGHTS BY DRUG
The global drug-coated balloons market by drug type is categorized into paclitaxel and sirolimus. The paclitaxel drug segment shows significant growth, with the fastest-growing CAGR during the forecast period. In drug-coated balloons, paclitaxel is an effective treatment for coronary in-stent restenosis. Globally, millions of people undergo percutaneous coronary intervention (PCI) annually, where paclitaxel-coated balloons are considered an effective treatment. This anti-neoplastic, cytotoxic drug binds to the microtubules in the cell mitosis procedure and restricts cell division and proliferation. It was the first developed drug for a drug-coated balloon module and is still widely used across the global markets. In DCB, paclitaxel is the most widely used drug due to its physiochemical characteristics. The lipophilicity of the drugs enables rapid penetration into the cell and supports longer antiproliferative action. Furthermore, the advancement in excipient for paclitaxel-coated blood, such as the development of urea, n-butyryl citrate, and acetyl tributyl citrate, delivers positive clinical outcomes and has proven to increase the effectivity of paclitaxel-coated balloons accelerating the segmental growth.
INSIGHTS BY END-USERS
The multi-specialty hospital end-user segment accounted for major global drug-coated balloons market share. Multi-specialty hospitals are leading revenue generators for DCB markets. Angioplasty procedures are commonly performed in multi-specialty hospitals across several health conditions where the uptake volume of DCB is higher than in specialty hospitals. Cardiologists in multi-specialty hospitals widely used drug-coated balloons for PCI procedures in PAD, CAD, and other diseases treatment and management of patients who are suffering from several consequences of cardiovascular diseases. The presence and access of skilled healthcare professionals and high-class services of angiogram, angioplasty, and cardiology interventions with deep understanding and expertise in CVD management get more patients' attention to multi-specialty hospitals than other healthcare settings. Multi-specialty hospitals offer high-class services, specialties, infrastructure, bulk-order medical devices, and more access and revenue growth opportunities. In addition, multi-specialty hospitals cover several cardiac procedures and diagnoses under one facility, which reduces the cost burden, travel, and challenges associated with diagnosis and related communication barriers. These settings help the segment to grow.
GEOGRAPHICAL ANALYSIS
North America accounted for the largest share and stands first in the global drug-coated balloons market. North America is expected to grow at the highest CAGR during the forecast period. The U.S. dominates the region due to the high volume of percutaneous coronary interventions, a large pool of patient population, and high healthcare expenditure regarding treating CAD PAD, which leads to demand for balloon angioplasties. More than 22 million people suffer from peripheral artery disease and witnessed several health risks. DCB is the preferred choice in PAD management in the region. Furthermore, several DCBs in PAD management have been approved in the U.S. in the past few years, accelerating the market growth.
COMPETITIVE LANDSCAPE
The global drug-coated balloons market report contains exclusive data on 25 companies. The market is fairly concentrated, with several prominent and upcoming players. Large corporations dominate the market. However, there are significant growth opportunities for new entrants. Though the market is dominated by major players, many investigational and small companies are coming into existence with innovative products and technologies. BD, Boston Scientific, B. Braun SE, Medtronic, Koninklijke Philips, and Biotronik are some leading companies accounting for significant shares in the global drug-coated balloons market. These vendors are continuously developing and investing in drug-coated balloons and are expected to dominate the market with continued engagement in advanced DCB development.
Frequently Asked Questions
How big is the global drug-coated balloons market?
What are the key drivers of the global drug-coated balloons market?
What is the growth rate of the global drug-coated balloons market?
Which region dominates the global drug-coated balloons market?
Who are the major players in the global drug-coated balloons market?
The global drug-coated balloons market size is expected to grow at a CAGR of approximately 15.72% from 2023 to 2029.
Base Year: 2023
Forecast Year: 2024-2029
The report considers the present scenario of the global drug-coated balloons market ket and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
VENDORS LIST
Key Vendors
- BD
- Boston Scientific
- B. Braun SE
- Medtronic
- Koninklijke Philips N.V.
- Biotronik
Other Prominent Vendors
- Biosensors International Group, Ltd.
- Terumo Corporation
- Concept Medical
- Cardionovum
- ENDOCOR GmbH & CO. KG
- iVascular
- Cordis
- Meril Life Sciences
- Nano Therapeutics
- Genesis MedTech Group
- INVAMED
- Abbott
- Laborie
- Translumina
- Acotec Scientific
- Lepu Medical Technology
- Balton
- ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
- AR Baltic Medic
SEGMENTATION & FORECAST
- By Indication
- Peripheral Artery Disease (PAD)
- Coronary Artery Disease (CAD)
- Other Indications
- By Drug
- Paclitaxel
- Sirolimus
- By End-users
- Multi-specialty Hospitals
- Specialty Hospitals
- By Geography
- North America
- The U.S.
- Canada
- Europe
- Germany
- The U.K.
- France
- Italy
- Spain
- APAC
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia
- North America
Exhibit 1: Projected Revenues of Drug-coated Balloons in Global (2020 – 2029; $ Mn)
Exhibit 2: Market Size & Forecast – Peripheral Artery Disease (2020 – 2029; $ Mn)
Exhibit 3: Market Size & Forecast – Coronary Artery Disease (2020 – 2029; $ Mn)
Exhibit 4: Market Size & Forecast – Other Indications (2020 – 2029; $ Mn)
Exhibit 5: Market Size & Forecast – Paclitaxel (2020 – 2029; $ Mn)
Exhibit 6: Market Size & Forecast – Sirolimus (2020 – 2029; $ Mn)
Exhibit 7: Market Size & Forecast – Multi-specialty Hospitals (2020 – 2029; $ Mn)
Exhibit 8: Market Size & Forecast – Specialty Hospitals (2020 – 2029; $ Mn)
Exhibit 9: Projected Revenues of Drug-coated Balloons in N. America (2020 – 2029; $ Mn)
Exhibit 10: Projected Revenues of Drug-coated Balloons in the US (2020 – 2029; $ Mn)
Exhibit 11: Projected Revenues of Drug-coated Balloons in Canada (2020 – 2029; $ Mn)
Exhibit 12: Projected Revenues of Drug-coated Balloons in Europe (2020 – 2029; $ Mn)
Exhibit 13: Projected Revenues of Drug-coated Balloons in Germany (2020 – 2029; $ Mn)
Exhibit 14: Projected Revenues of Drug-coated Balloons in France (2020 – 2029; $ Mn)
Exhibit 15: Projected Revenues of Drug-coated Balloons in the UK (2020 – 2029; $ Mn)
Exhibit 16: Projected Revenues of Drug-coated Balloons in Italy (2020 – 2029; $ Mn)
Exhibit 17: Projected Revenues of Drug-coated Balloons in Spain (2020 – 2029; $ Mn)
Exhibit 18: Projected Revenues of Drug-coated Balloons in APAC (2020 – 2029; $ Mn)
Exhibit 19: Projected Revenues of Drug-coated Balloons in Japan (2020 – 2029; $ Mn)
Exhibit 20: Projected Revenues of Drug-coated Balloons in China (2020 – 2029; $ Mn)
Exhibit 21: Projected Revenues of Drug-coated Balloons in South Korea (2020 – 2029; $ Mn)
Exhibit 22: Projected Revenues of Drug-coated Balloons in Australia (2020 – 2029; $ Mn)
Exhibit 23: Projected Revenues of Drug-coated Balloons in India (2020 – 2029; $ Mn)
Exhibit 24: Projected Revenues of Drug-coated Balloons in L. America (2020 – 2029; $ Mn)
Exhibit 25: Projected Revenues of Drug-coated Balloons in Brazil (2020 – 2029; $ Mn)
Exhibit 26: Projected Revenues of Drug-coated Balloons in Mexico (2020 – 2029; $ Mn)
Exhibit 27: Projected Revenues of Drug-coated Balloons in Argentina (2020 – 2029; $ Mn)
Exhibit 28: Projected Revenues of Drug-coated Balloons in MEA (2020 – 2029; $ Mn)
Exhibit 29: Projected Revenues of Drug-coated Balloons in Turkey (2020 – 2029; $ Mn)
Exhibit 30: Projected Revenues of Drug-coated Balloons in S. Africa (2020 – 2029; $ Mn)
Exhibit 31: Projected Revenues of Drug-coated Balloons in Saudi Arabia (2020 – 2029; $ Mn)
Tables
Table 1: Key Market Trends in Drug-coated Balloons Market
Table 2: Key Market Enablers in Drug-coated Balloons Market
Table 3: Key Market Constraints in Drug-coated Balloons Market
Table 4: Strategic Recommendations in Drug-coated Balloons Market
CHAPTER 1: Drug-coated Balloons Market Overview
- Executive Summary
- Key Findings
CHAPTER 2: Drug-coated Balloons Market
- GLOBAL: Projected Revenue of Drug-coated Balloons Market (2020-2029; $ Millions)
CHAPTER 3: Drug-coated Balloons Market Segmentation Data
- GLOBAL: Projected Revenue by Indication (2020-2029; $ Millions)
- Peripheral Artery Disease
- Coronary Artery Disease
- Other Indications
- GLOBAL: Projected Revenue by Drug Type (2020-2029; $ Millions)
- Paclitaxel
- Sirolimus
- GLOBAL: Projected Revenue by End-users (2020-2029; $ Millions)
- Multi-specialty Hospitals
- Specialty Hospitals
CHAPTER 4: Key Regions Overview
- North America: Projected Revenue of Drug-coated Balloons Market (2020-2029; $ Millions)
- Projected Revenue of Drug-coated Balloons Market in the US
- Projected Revenue of Drug-coated Balloons Market in Canada
- Europe: Projected Revenue of Drug-coated Balloons Market (2020-2029; $ Millions)
- Projected Revenue of Drug-coated Balloons Market in Germany
- Projected Revenue of Drug-coated Balloons Market in France
- Projected Revenue of Drug-coated Balloons Market in the UK
- Projected Revenue of Drug-coated Balloons Market in Italy
- Projected Revenue of Drug-coated Balloons Market in Spain
- APAC: Projected Revenue of Drug-coated Balloons Market (2020-2029; $ Millions)
- Projected Revenue of Drug-coated Balloons Market in Japan
- Projected Revenue of Drug-coated Balloons Market in China
- Projected Revenue of Drug-coated Balloons Market in South Korea
- Projected Revenue of Drug-coated Balloons Market in Australia
- Projected Revenue of Drug-coated Balloons Market in India
- Latin America: Projected Revenue of Drug-coated Balloons Market (2020-2029; $ Millions)
- Projected Revenue of Drug-coated Balloons Market in Brazil
- Projected Revenue of Drug-coated Balloons Market in Mexico
- Projected Revenue of Drug-coated Balloons Market in Argentina
- Middle East & Africa: Projected Revenue of Drug-coated Balloons Market (2020-2029; $ Millions)
- Projected Revenue of Drug-coated BalloonsMarket in Turkey
- Projected Revenue of Drug-coated BalloonsMarket in South Africa
- Projected Revenue of Drug-coated BalloonsMarket in Saudi Arabia
CHAPTER 5: Drug-coated Balloons Market Prospects & Opportunities
- Drug-coated Balloons Market Opportunities & Trends
- Drug-coated Balloons Market Drivers
- Drug-coated Balloons Market Constraints
CHAPTER 6: Drug-coated Balloons Industry Overview
- Drug-coated Balloons Market - Competitive Landscape
- Drug-coated Balloons Market – Key Vendor Profiles
- Drug-coated Balloons Market – Other Prominent Vendors
- Drug-coated Balloons Market - Key Strategic Recommendations
CHAPTER 7: Appendix
- Research Methodology
- Abbreviations
- About Arizton
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the global drug-coated balloons market?
What are the key drivers of the global drug-coated balloons market?
What is the growth rate of the global drug-coated balloons market?
Which region dominates the global drug-coated balloons market?
Who are the major players in the global drug-coated balloons market?